driving disease

driving disease

see ovine pulmonary adenomatosis.
References in periodicals archive ?
we anticipate that this work will fundamentally shift our paradigms of infectious disease pathogenesis and lay the groundwork for the development of a new generation of therapeutic agents targeting the specific host-pathogen interactions ultimately driving disease.
ddPCR testing of cellfree DNA in blood or other fluids is especially well suited for diagnosing and monitoring treatment response in melanoma because only a small number of recurrent mutations are responsible for driving disease in the majority of these patients' tumors.
Cambridge, Massachusetts-based cancer and immune-mediated disease treatment developer and gene control medicine specialist Syros Pharmaceuticals (NASDAQ: SYRS) has discovered alterations in regulatory regions of the genome in T cells from patients with systemic lupus erythematosus (SLE), revealing genes critical for activating T cells and driving disease, the company said.
However, while GWAS was an important first line of investigations of the genetics of CAD, in order to translate these risk markers into opportunities for new diagnostics and therapies, we must now move into a new phase of discovery and identify the genes perturbed by these DNA variants responsible for driving disease development.
The strength of systems biology has been hypothesis-free discovery, which enables researchers to reduce bias in their studies and find unlikely relationships driving disease pathology.
The receptor's key role in driving disease pathology has been implicated through studies using MAbs that neutralize IL-17 activity.
Our next step is to understand if these play a role in driving disease," he added.
This lack of consolidation makes it unclear how these different approaches relate in terms of understanding the mechanisms driving disease emergence.
human activities are the most potent factors driving disease emergence
In clinical trials using monoclonal antibodies which neutralize IL-17 activity, its major role in driving disease pathology has been concerned.
The receptor's key role in driving disease pathology has been implicated through clinical studies using monoclonal antibodies that neutralize IL-17 activity.
The results from the Company's Phase 2a study suggest that immune system hyperactivation driving disease progression can be specifically, rapidly and effectively reduced by AV-HALTs, resulting in a proportional restoration of immune system damage.